Mol Ther Nucleic Acids
March 2024
Activating cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) holds great potential for cancer immunotherapy by eliciting type-I interferon (IFN-I) responses. Yet, current approaches to cGAS-STING activation rely on STING agonists, which suffer from difficult formulation, poor pharmacokinetics, and marginal clinical therapeutic efficacy. Here, we report nature-inspired oligonucleotide, Svg3, as a cGAS agonist for cGAS-STING activation in tumor combination immunotherapy.
View Article and Find Full Text PDFCurrent cancer immunotherapy (e.g., immune checkpoint blockade (ICB)) has only benefited a small subset of patients.
View Article and Find Full Text PDFCancer immunotherapy has shown great potential as witnessed by an increasing number of immuno-oncology drug approvals in the past few years. Meanwhile, the field of nucleic acid therapeutics has made significant advancement. Nucleic acid therapeutics, such as plasmids, antisense oligonucleotides (ASO), small interfering RNA (siRNA) and microRNA, messenger RNA (mRNA), immunomodulatory DNA/RNA, and gene-editing guide RNA (gRNA) are attractive due to their versatile abilities to alter the expression of target endogenous genes or even synthetic genes, and modulate the immune responses.
View Article and Find Full Text PDFFour types of middle-pressure chromatogram isolated gels are evaluated for adsorption or desorption characteristics of ginsenosides from Panax ginseng. Among them, SP207SS and SP2MGS were selected for dynamic investigations based on their static adsorption or desorption capacity of total ginsenoside. Their adsorption kinetics was better explained by pseudosecond-order model and isotherms were preferably fitted to Langmuir model.
View Article and Find Full Text PDFDermatol Nurs
December 2002
The skin reflects the internal well-being of the body and can develop manifestations of systemic illness. The nurse's ability to recognize and accurately describe lesions can lead to prompt diagnosis and treatment of conditions, helping the patient to avoid discomfort, systemic illness, or death. To accurately describe skin findings, the nurse should know the names and defining characteristics of certain primary lesions.
View Article and Find Full Text PDF